Browse by Section 100 Item List
Highly Specialised Drugs Program (Public Hospital)
For Pharmaceutical Benefits Scheme (PBS) Highly Specialised Drugs prescribed through public hospitals, claiming and approval of authority prescriptions is administered by Services Australia. Highly Specialised Drugs prescribed in public hospitals are Authority Required items. Application for authorisation can be made by either:
- posting an Authority Prescription form and other application form(s), where applicable to Services Australia
- using the form upload facility in Health Professional Online Services (HPOS)
- using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS)
- using the Services Australia free-call service for PBS Complex Drugs Programs enquiries (1800 700 270) or
- using the appropriate Streamlined code.
Prescribers must quote the provider number of the hospital when applying. Maximum quantities and repeats for Highly Specialised Drugs are listed in the PBS Schedule. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats.
Public hospital prescriptions for Highly Specialised Drugs can be dispensed by public hospital pharmacies and some of these prescriptions can be dispensed by a community pharmacy. A patient may be required to pay a contribution for each supply of a highly specialised drug at a similar rate to the PBS. Commonwealth subsidy is not available for hospital in-patients.
Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.
- Legend
- MPMedical Practitioner
| Prescriber code | Item code | Name, manner of administration and form & strength | Max qty packs |
Max qty units |
No. of repeats |
|---|---|---|---|---|---|
| MP | 13825P | NATALIZUMABnatalizumab 150 mg/mL injection, 2 x 1 mL syringes | 1 | 2 | 5 |
| MP | 9505G | NATALIZUMABnatalizumab 300 mg/15 mL injection, 15 mL vial | 1 | 1 | 5 |
| MP | 13817F | NIVOLUMAB + RELATLIMABnivolumab 240 mg/20 mL + relatlimab 80 mg/20 mL injection, 20 mL vial | 2 | 2 | 11 |
| MP | 13830X | NIVOLUMAB + RELATLIMABnivolumab 240 mg/20 mL + relatlimab 80 mg/20 mL injection, 20 mL vial | 2 | 2 | 8 |
| MP | 11363C | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
| MP | 11378W | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 0 |
| MP | 12177X | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
| MP | 12972R | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
| MP | 13052Y | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
| MP | 13068T | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 0 |
| MP | 13083N | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
| MP | 13084P | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 0 |
| MP | 14095W | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 0 |
| MP | 14099C | NUSINERSENnusinersen 12 mg/5 mL intrathecal injection, 5 mL vial | 1 | 1 | 3 |
